News | February 10, 2011

New Bill Aims to Promote Domestic Isotope Production

February 10, 2011 – A new bill introduced to the U.S. Senate aims to promote sustainable, domestic production of the medical isotope molybdenum-99 (Mo-99). The bill, also known as the American Medical Isotopes Production Act of 2011, was introduced by Sen. Jeff Bingaman (D-N.M.) and Sen. Lisa Murkowski (R-Ark.).

Bingaman is chair of the Senate Committee on Energy and Natural Resources.

Mo-99 is an isotope that decays to technetium-99m (Tc-99m), which is used in more than 16.7 million procedures in the United States each year. Tc-99m is utilized in the detection of heart disease, detection and staging of cancer, detection of thyroid disease, study of brain and kidney function, and imaging of stress fractures.

There are currently only six foreign producers of Mo-99 approved by the U.S. Food and Drug Administration (FDA) to import it into the United States. No domestic facilities exist that are dedicated to the production of Mo-99 for medical uses. Aging foreign reactors regularly experience significant ongoing maintenance issues, frequently causing these reactors to go off-line. In 2009-2010, the Unites States experienced a shortage of Mo-99, which led to the disruption or delay of nuclear medicine procedures for an estimated 50,000 patients each day.

"In order to ensure that our patients can receive the best medical care, it’s essential that a reliable supply of Mo-99 be available in the United States," said Robert Atcher, chair of SNM’s Government Relations Committee. "The best way for that to be achieved is by developing production facilities for Mo-99 domestically."

The American Medical Isotopes Production Act seeks to establish a technology-neutral program to support the production of Mo-99 for medical uses in the United States by nonfederal entities. The bill also calls for the United States to condition and phase out the export of highly enriched uranium for the production of medical isotopes over a period of seven years.

A bill is expected to be introduced in the House of Representatives in coming weeks.

For more information: www.snm.org

Related Content

NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
Overlay Init